Acute and chronic effects of levosimendan in the ZSF1 obese rat model of heart failure with preserved ejection fraction

• Tipo: Artigo em Revista Científica Internacional
• Data: 2024

Autores

Moreira-Costa, L (Autor) Outra; Tavares-Silva, M (Autor) FMUP; Almeida-Coleho, J (Autor) Outra; Gonçalves, A (Autor) Outra; Trindade, F (Autor) Outra; Vasques-Nóvoa, F (Autor) FMUP; Sosa-Mendes, C (Autor) Outra; Leite, S (Autor) FMUP; Vitorino, R (Autor) FMUP; Falcao Pires, I (Autor) FMUP; Leite-Moreira AF (Autor) FMUP; Andre P Lourenco (Autor) FMUP

Revista

Título: European Journal of Pharmacology

Vol. 966

ISSN: 0014-2999

Editora: Elsevier

Indexação

ISI Web of Knowledge - 1 Citação

Scopus - 1 Citação

Outras Informações

ID Authenticus: P-00Z-XG6

DOI: 10.1016/j.ejphar.2024.176336

Abstract (EN): Heart failure with preserved ejection fraction (HFpEF) is a syndrome characterized by impaired cardiovascular reserve in which therapeutic options are scarce. Our aim was to evaluate the inodilator levosimendan in the ZSF1 obese rat model of HFpEF. Twenty-week-old male Wistar-Kyoto (WKY), ZSF1 lean (ZSF1 Ln) and ZSF1 obese rats chronically treated for 6-weeks with either levosimendan (1 mg/kg/day, ZSF1 Ob + Levo) or vehicle (ZSF1 Ob + Veh) underwent peak-effort testing, pressure-volume (PV) haemodynamic evaluation and echocardiography (n = 7 each). Samples were collected for histology and western blotting. In obese rats, skinned and intact left ventricular (LV) cardiomyocytes underwent in vitro functional evaluation. Seven additional ZSF1 obese rats underwent PV evaluation to assess acute levosimendan effects (10 mu g/kg + 0.1 mu g/kg/min). ZSF1 Ob + Veh presented all hallmarks of HFpEF, namely effort intolerance, elevated end-diastolic pressures and reduced diastolic compliance as well as increased LV mass and left atrial area, cardiomyocyte hypertrophy and increased interstitial fibrosis. Levosimendan decreased systemic arterial pressures, raised cardiac index, and enhanced LV relaxation and diastolic compliance in both acute and chronic experiments. ZSF1 Ob + Levo showed pronounced attenuation of hypertrophy and interstitial fibrosis alongside increased effort tolerance (endured workload raised 38 %) and maximum O2 consumption. Skinned cardiomyocytes from ZSF 1 Ob + Levo showed a downward shift in sarcomere length-passive tension relationship and intact cardiomyocytes showed decreased diastolic Ca2+ levels and enhanced Ca2+ sensitivity. On molecular grounds, levosimendan enhanced phosphorylation of phospholamban and mammalian target of rapamycin. The observed effects encourage future clinical trials with levosimendan in a broad population of HFpEF patients.

Idioma: Inglês

Tipo (Avaliação Docente): Científica

Nº de páginas: 11